Shots:

• The companies collaborate to evaluate the combination of BioInvent's BI-1206 and MSD’s Keytruda in a P-l/lla clinical study for patients with solid tumors- prior treated with anti-PD-1 or anti-PD-L1 Ab
• The collaboration allows BioInvent to expand the clinical development of BI-1206 against solid tumors. The preclinical data demonstrated that BI-1206 addresses the mechanism of resistance to PD-1 inhibition
• BI-1206 is an anti-FcγRlIB Ab- currently being evaluated in NHL and CLL while Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Rasayanika